Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00410293
Status:
COMPLETED
Last Update Posted:
2006-12-12
First Post:
2006-12-11
Brief Title:
NT-proBNP in Acute Dyspnea Effects on Treatment Hospitalisation and Costs
Sponsor:
Erasmus Medical Center
Organization:
Erasmus Medical Center
Study Overview
Official Title:
NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea Evaluation of Effects on Treatment Hospitalisation Rate and Costs
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Diagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide NT-proBNP can be demonstrated The use of NT-proBNP as a biomarker for heart failure in patients presenting to the emergency department with dyspnea might improve care and reduce length of hospital stay
To investigate the effect of NT-proBNP testing on patient care and time to discharge the NT-proBNP test will be randomized In patients in the study group the NT-proBNP plasma level is determined at admission and the physician in charge will immediately receive the result of the test In patients in the control group blood will be sampled but the physician will recieve no information on the NT-proBNP plasma level
In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment time to discharge and costs
To investigate the effect of NT-proBNP testing on patient care and time to discharge the NT-proBNP test will be randomized In patients in the study group the NT-proBNP plasma level is determined at admission and the physician in charge will immediately receive the result of the test In patients in the control group blood will be sampled but the physician will recieve no information on the NT-proBNP plasma level
In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment time to discharge and costs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None